ArticleJournal of cheminformatics2026
Enzyformer: a two-stage pretrained model for enzymatic retrosynthesis.
Article in Journal of cheminformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Although enzymatic retrosynthesis planning is widely used to accelerate drug synthesis and discovery, it still faces key challenges, including limited knowledge transfer from general chemical space and incomplete EC number prediction. Here, we introduce Enzyformer, an innovative model that integrates the pretraining of molecules and reactions to capture both the syntax of SMILES and the transformation rules of organic reactions. With this two-stage pretraining strategy, Enzyformer improves top-1 and top-10 accuracies in retrosynthesis prediction by 7.5% and 11.7%, respectively, compared with the baseline R-SMILES. In addition, our pipeline also includes EC number prediction as a sequential task, using a contrastive learning model to improve performance on ECREACT dataset. With the contrastive learning model, we achieve the highest average F1-score of 0.924 for first-level EC number prediction. In conclusion, Enzyformer offers a promising solution for improving the accuracy and interpretability of enzymatic retrosynthesis prediction, which may help to reduce researchers' workload and cost while accelerating drug design and mitigating the environmental impact of drug synthesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.